Verastem, Inc.

Healthcare · Biotechnology · United States

Last price 9.75 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.18B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine ki...